Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study

10.1016/j.clinthera.2013.02.007

Saved in:

Bibliographic Details
Main Authors:	Peveling-Oberhag, J., Zeuzem, S., Yong, W.P., Kunz, T., Paquet, T., Bouillaud, E., Urva, S., Anak, O., Sellami, D., Kobalava, Z.
Other Authors:	CANCER SCIENCE INSTITUTE OF SINGAPORE
Format:	Article
Published:	2014
Subjects:	Healthy subjects Hepatic impairment Molecular therapeutics Pharmacokinetics
Online Access:	http://scholarbank.nus.edu.sg/handle/10635/116996
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-116996
record_format	dspace
spelling	sg-nus-scholar.10635-1169962023-10-25T07:39:10Z Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study Peveling-Oberhag, J. Zeuzem, S. Yong, W.P. Kunz, T. Paquet, T. Bouillaud, E. Urva, S. Anak, O. Sellami, D. Kobalava, Z. CANCER SCIENCE INSTITUTE OF SINGAPORE Healthy subjects Hepatic impairment Molecular therapeutics Pharmacokinetics 10.1016/j.clinthera.2013.02.007 Clinical Therapeutics 35 3 215-225 CLTHD 2014-12-12T08:00:10Z 2014-12-12T08:00:10Z 2013-03 Article Peveling-Oberhag, J., Zeuzem, S., Yong, W.P., Kunz, T., Paquet, T., Bouillaud, E., Urva, S., Anak, O., Sellami, D., Kobalava, Z. (2013-03). Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study. Clinical Therapeutics 35 (3) : 215-225. ScholarBank@NUS Repository. https://doi.org/10.1016/j.clinthera.2013.02.007 01492918 http://scholarbank.nus.edu.sg/handle/10635/116996 000318197400004 Scopus
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	Healthy subjects Hepatic impairment Molecular therapeutics Pharmacokinetics
spellingShingle	Healthy subjects Hepatic impairment Molecular therapeutics Pharmacokinetics Peveling-Oberhag, J. Zeuzem, S. Yong, W.P. Kunz, T. Paquet, T. Bouillaud, E. Urva, S. Anak, O. Sellami, D. Kobalava, Z. Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study
description	10.1016/j.clinthera.2013.02.007
author2	CANCER SCIENCE INSTITUTE OF SINGAPORE
author_facet	CANCER SCIENCE INSTITUTE OF SINGAPORE Peveling-Oberhag, J. Zeuzem, S. Yong, W.P. Kunz, T. Paquet, T. Bouillaud, E. Urva, S. Anak, O. Sellami, D. Kobalava, Z.
format	Article
author	Peveling-Oberhag, J. Zeuzem, S. Yong, W.P. Kunz, T. Paquet, T. Bouillaud, E. Urva, S. Anak, O. Sellami, D. Kobalava, Z.
author_sort	Peveling-Oberhag, J.
title	Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study
title_short	Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study
title_full	Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study
title_fullStr	Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study
title_full_unstemmed	Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study
title_sort	effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study
publishDate	2014
url	http://scholarbank.nus.edu.sg/handle/10635/116996
_version_	1781789578770776064

Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study

Similar Items